Skip to main content
FDA grants breakthrough status to ArcherDx's companion diagnostic assay

ArcherDx has received breakthrough designation from the FDA for its companion diagnostic assay to analyze over 50 genes to identify alterations in somatic tumor DNA in plasma and in RNA or DNA taken from cancer tissue. Results generated by the sequencing-based test can be used to identify advanced non-small cell lung cancer patients who could benefit from a certain targeted therapy.

Full Story: